News

Beximco Pharma receives US FDA approval for Flecainide Acetate Tabs

September 21st, 2020- Bayshore Pharmaceuticals’ manufacturing partner, Beximco Pharmaceuticals, received US FDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats. Product launch timing will be disclosed shortly.

https://thefinancialexpress.com.bd/home/beximco-pharma-receives-us-fda-approval-for-flecainide-1600689153?amp=true

Bayshore Pharmaceuticals Granted Etodolac ANDA Approvals
Bayshore Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 750 mg Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity